索磷布韦联合维帕他韦(含或不含伏西拉韦)治疗慢性丙型肝炎病毒感染后的患者报告结局
基于POLARIS-1和POLARIS-4两项多中心、盲法、国际3期试验的748例经直接抗病毒药物治疗的慢性HCV感染患者,评估索磷布韦联合维帕他韦(含或不含伏西拉韦)治疗期间及停药后12周患者报告结局的变化。结果显示治疗组部分PRO评分较安慰剂组改善,两治疗组间PRO无差异,治疗与更高PRO评分相关。
要点
- 索磷布韦+维帕他韦+伏西拉韦组胃肠道症状多于索磷布韦+维帕他韦组或安慰剂组(P=.0001)
- 索磷布韦+维帕他韦组SVR12为90.1%,索磷布韦+维帕他韦+伏西拉韦组为96.9%(P=.0008)
- 两治疗组间PRO评分无差异(均P>.05),治疗与较安慰剂更高的PRO评分相关(beta最高5.1,P<.05)
核心结论
- 在两项3期临床试验的慢性HCV感染(任何基因型)患者中,索磷布韦联合维帕他韦(含或不含伏西拉韦)较安慰剂提高PRO评分,提示这些方案在治疗期间及获得SVR后具有综合获益。
研究设计与样本
- 研究为2项多中心、盲法、国际3期试验(POLARIS-1和POLARIS-4),纳入748例既往接受直接抗病毒药物治疗的慢性HCV感染(任何基因型)患者。
- 索磷布韦+维帕他韦+伏西拉韦组445例,索磷布韦+维帕他韦组151例,安慰剂组152例;59%为HCV基因1型,43%有代偿性肝硬化。
- 患者在基线、治疗期间及随访期间完成SF-36、FACIT-F、CLDQ-HCV和WPAI:SHP问卷。
主要发现
- 各组基线临床或人口学特征及PRO评分无差异(均P>.05)。
- 索磷布韦+维帕他韦+伏西拉韦组胃肠道症状多于索磷布韦+维帕他韦组或安慰剂组(P=.0001)。
- 索磷布韦+维帕他韦组SVR12为90.1%,索磷布韦+维帕他韦+伏西拉韦组为96.9%(P=.0008)。
- 治疗12周后,两治疗组部分PRO评分改善(0-100分制上提高2.5分或9.1分,P<.05),安慰剂组无改善。
- 治疗结束后PRO评分改善持续或进一步增加(治疗结束后12周最高增加11.1分,治疗结束后24周最高增加16.6分;除2项PRO外均P<.05)。
临床怎么用
- 作者认为这些方案在治疗期间及获得SVR后具有综合获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Chronic infection with hepatitis C virus (HCV) has many hepatic and extrahepatic manifestations, measured by patient-reported outcomes (PROs). We measured changes in PROs during HCV treatment with recently developed pangenotypic regimens and from a sustained virologic response 12 weeks after treatment ended (SVR12). METHODS: We collected PRO data from 2 multi-center, blinded, international phase 3 trials of sofosbuvir, velpatasvir, and voxilaprevir, from 748 patients previously treated with direct-acting antivirals for chronic infection with HCV of any genotype (59% HCV genotype 1, 43% with compensated cirrhosis) (POLARIS-1 and POLARIS-4). The combination of sofosbuvir, velpatasvir, and voxilaprevir was given to 445 patients, the combination of sofosbuvir and velpatasvir to 151 patients, and placebo to 152 patients. Patients completed the SF-36, FACIT-F, CLDQ-HCV, and WPAI:SHP questionnaires at baseline, during treatment, and during the follow-up period. RESULTS: There was no difference in baseline clinical or demographic features or PRO scores among the groups (all P > .05). The group that received the combination of sofosbuvir, velpatasvir, and voxilaprevir had more gastrointestinal symptoms than the groups that received sofosbuvir and velpatasvir or placebo (P = .0001). An SVR12 was achieved by 90.1% of patients who received sofosbuvir and velpatasvir vs 96.9% of patients who received sofosbuvir, velpatasvir, and voxilaprevir (P = .0008). After 12 weeks of treatment, some PRO scores improved in both treatment groups (by 2.5 or by 9.1 points, on a 0-100 scale; P < .05) but not in the placebo group. All increases in PRO scores were sustained or increased after treatment ended (an increase of up to 11.1 points at 12 weeks after treatment and an increase of up to 16.6 points at 24 weeks after treatment ended) (P < .05 for all but 2 PROs). There were no differences in PROs between the sofosbuvir and velpatasvir group vs the sofosbuvir, velpatasvir, and voxilaprevir group (all P > .05). In multivariate analysis, after adjustment for clinical and demographic factors and baseline PRO scores, receiving treatment was associated with higher PROs scores than receiving placebo (beta as high as 5.1) (P < .05). CONCLUSIONS: In an analysis of data from 2 phase 3 clinical trials of patients with chronic HCV infection of any genotype, we found the combination of sofosbuvir, velpatasvir, with or without voxilaprevir, to increase PRO scores compared with placebo. These findings indicate the comprehensive benefit of these regimens during treatment and after SVR.
引用
- Younossi ZM, Stepanova M, Gordon S, et al. Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. Clin Gastroenterol Hepatol. 2017. PMID: 29155352. doi:10.1016/j.cgh.2017.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。